BDTX

Black Diamond Therapeutics, Inc.

• NASDAQ·1d ago

  Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?

• Seeking Alpha·03/25 12:53

  Black Diamond Therapeutics: Market Is Yawning About These Data, But I See Opportunity

• Simply Wall St·03/18 02:15

  Black Diamond Therapeutics (BDTX) Profit Swing To US$0.81 EPS Challenges Bearish Earnings Narratives

• Dow Jones·03/17 12:45

  Black Diamond Theraptcs Is Maintained at Outperform by Wedbush

• Dow Jones·03/17 12:45

  Black Diamond Theraptcs Price Target Raised to $14.00/Share From $13.00 by Wedbush

• Benzinga·03/17 12:35

  Wedbush Maintains Outperform on Black Diamond Therapeutic, Raises Price Target to $14

• TipRanks·03/17 11:51

  Black Diamond Therapeutics price target raised to $14 from $13 at Wedbush

• TipRanks·03/17 11:35

  Piper Sandler Sticks to Its Buy Rating for Black Diamond Therapeutics (BDTX)

• TipRanks·03/17 11:15

  Stifel Nicolaus Keeps Their Buy Rating on Black Diamond Therapeutics (BDTX)

• TipRanks·03/17 03:25

  Black Diamond Therapeutics (BDTX) Receives a Buy from TD Cowen

• Seeking Alpha·03/16 21:00

  Black Diamond Therapeutics GAAP EPS of -$0.27 misses by $0.09

• Reuters·03/16 20:12

  Black Diamond Therapeutics Q4 net loss narrows, full-year profit turns positive

• Dow Jones·03/16 20:10

  *Black Diamond Theraptcs Sees Cash Runway Sufficient to Fund Ops Into 2H of 2028 >BDTX

• Dow Jones·03/16 20:09

  *Black Diamond: Clinical Update on Track for 2Q for Phase 2 Trial of Silevertinib in Patients With Non-Classical EGFRm NSCLC

• TipRanks·03/16 20:05

  Black Diamond Therapeutics reports Q4 EPS (27c), consensus (17c)